**Natera Unveils Updated ALTAIR Clinical Trial Analyses at ASCO‑GI 2026**

Natera, Inc. (NASDAQ: NTRA), a global leader in cell‑free DNA and precision medicine, announced updated findings from the Phase III ALTAIR clinical trial that will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO‑GI) from January 8‑10, 2026. The ALTAIR trial (NCT04457297) is a randomized, double‑blind study evaluating the impact of Trifluridine/Tipiracil (FTD/TPI) on molecular recurrence in patients with stage I‑IV colorectal cancer who tested positive with Natera’s Signatera™ circulating tumor DNA (ctDNA) assay. A post‑hoc blinded central radiographic review revealed that FTD/TPI significantly improved disease‑free survival (DFS) versus placebo, with median DFS of 9.23 months compared to 5.55 months and a hazard ratio (HR) of 0.75 (95 % CI: 0.55‑0.98; P = 0.0406), marking a meaningful update from earlier analyses that showed only numerical benefit. In addition to the ALTAIR results, Natera will highlight a large‑scale study showing that rapid increases in Signatera ctDNA levels (doubling time in one month or less) are linked to shorter recurrence‑free survival, underscoring the value of ctDNA dynamics in relapse risk assessment and personalized management strategies for colorectal cancer patients. #Natera #ColorectalCancer #ASCOGI2026 #ClinicalTrialResults #SlimScan #GrowthStocks #CANSLIM